Author

David Salek

Observed name: Salek, David

OpenAlex ID: A5149167602

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

2012 · d’Amore, Francesco, Leppa, Sirpa, et al. · GRO

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant

2011 · d’Amore, Francesco, da Silva, Maria Gomes, et al. · GRO

Works count: 2

Citation count:

H-index:

I10-index: